



**VIJAYA
DIAGNOSTIC
CENTRE**

July 28, 2025

The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: **VIJAYA**

The Corporate Relations Department,
BSE Limited
BSE Scrip Code: **543350**

Dear Sir/Madam,

Subject: Outcome of the Board Meeting held on Monday, July 28, 2025

Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time.

We hereby inform you that, the Board of Directors at their meeting held today i.e., on **Monday, July 28, 2025**, has inter-alia considered and approved the following:

1. The Unaudited Financial Results of the Company for the first quarter ended June 30, 2025. In terms of the above, we enclose herewith the following:
 - a. Unaudited Standalone and Consolidated Financial Results of the Company for the first quarter ended June 30, 2025; and
 - b. Limited review Reports on the Standalone & Consolidated Financial Results for the first quarter ended 30 June 2025.
2. Grant of 2,500 (Two Thousand Five Hundred only) Employee Stock Options (ESOPs) under the “**VDCL Employee Stock Option Plan 2018**”. These options are convertible into 2,500 equity shares of face value ₹1/- each.

Further, the grant of the above stock options is in line with the provisions of the SEBI (Share Based Employee Benefits & Sweat Equity) Regulations, 2021 as amended from time to time. The Disclosure as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is annexed herewith as **Annexure-A**.

3. Appointment of M/s. Balaramakrishna & Associates, Practicing Company Secretaries, having Firm Registration No. S2021TL825900 as the Secretarial Auditor of the Company for a period of five (5) consecutive financial years commencing from FY 2025-26 to FY 2029-30.



VIJAYA[®]
DIAGNOSTIC
CENTRE

The disclosure required under Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure-B**.

The Board Meeting commenced at 12:00 hrs and concluded at 13:15 hrs.

Kindly take the same on record.

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

Hansraj Singh
Company Secretary & Compliance Officer
M. No. F11438

Encl.: As above



Annexure - A

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III

S. No.	Particulars	Details
1.	Brief details of options granted	2,500 (Two Thousand Five Hundred only) Employee Stock Options (ESOPs) granted to the eligible employee of the company under “VDCL Employee Stock Option Plan 2018”
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021	Yes
3.	Total number of shares covered by these options	2,500 (Two Thousand Five Hundred only) of face value of ₹1/- each of the Company
4.	Pricing formula (<i>Exercise Price</i>)	The said ESOPs are being granted at ₹780/- (Rupees Seven Hundred and Eighty only) per option. The said price is the average closing price of the shares during the three (3) months preceding the month of the grant date and after providing a discount of 20%.
5.	Options vested	Not applicable <i>Options will start vesting after a period of one (1) year from the date of grant.</i>
6.	Time within which option may be exercised	Options shall be exercised from the date of the respective vesting of options and shall be exercised within the ‘ <u>exercise period.</u> ’ <i>Exercise Period – means the period of Ten (10) years from the grant date.</i>
7.	Options exercised	Not Applicable
8.	Money realized by exercise of options	Not Applicable
9.	The total number of shares arising as a result of exercise of option	Not Applicable
10.	Options lapsed	Not Applicable
11.	Variation of terms of options	Not Applicable
12.	Brief details of significant terms	VDCL Employee Stock Option Plan 2018 (“ the plan ”) is administered and implemented by the Nomination and Remuneration Committee of the Board of Directors in accordance with the plan.



		<p>The grant of options is based on the eligibility criteria as mentioned in the plan.</p> <p>Other significant terms of the Plan are as follows:</p> <ul style="list-style-type: none"> • Acceptance of the Grant: on or before the "Closing Date" which shall not be more than Thirty (30) days from the date of issuance of Grant Letter. • Minimum Vesting Period: One (1) Year From the date of Grant of ESOPs. • Vesting Schedule: under the plan, the company has formulated a total of six (6) different categories of ESOP schemes for the purposes of vesting and exercise of ESOPs for different categories of employees. The ESOPs shall vest as per the vesting schedule in the manner as defined under the respective scheme. <p>The current grant of ESOPs is being made under the ESOP scheme-5. For details pertaining to the vesting schedule of the aforesaid schemes, please refer to the note.</p> <ul style="list-style-type: none"> • The Shares arising out of exercise of vested options shall not be locked in.
13.	Subsequent changes or cancellation or exercise of such options	Not Applicable
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not Applicable

Note:

Sl. No.	Particulars	Scheme 5
1.	Nature of Options	Time based options
2.	Category of employees to be considered	Employees of Support functions (Finance & Accounts, IT, Strategy, Operations, etc.)



3.	Vesting Schedule	1st Year – 25% 2nd Year – 25% 3rd Year – 50%
----	-------------------------	--



Disclosure pertaining to Appointment

S. No.	Particulars	Details
1.	Reason for Change viz. appointment, resignation, removal, death or otherwise	Appointment of M/s. Balaramakrishna & Associates, Practicing Company Secretaries, as the Secretarial Auditors of the Company, subject to approval of shareholders of the Company at the ensuing Annual General Meeting.
2.	Date of appointment and term of appointment	The Board of Directors of the Company at its meeting held today i.e., July 28, 2025, based on the recommendation of the Audit Committee, approved the appointment of M/s. Balaramakrishna & Associates, Practicing Company Secretaries, having Firm Registration No. S2021TL825900 as the Secretarial Auditors of the Company for a period of five (5) consecutive financial years commencing from FY 2025-26 to FY 2029-30.
3.	Brief Profile	<p>Balarama Krishna Desina, Practicing Company Secretary, a Fellow Member of the Institute of Company Secretaries of India, New Delhi, ICSI empanelled Peer Reviewer, Proprietor of Balaramakrishna & Associates, a fast growing practicing Company Secretary Firm situated in Hyderabad, Founder and Managing partner of BK Corporate Consultants LLP which is providing Consultancy services in various fields to all the Body Corporates across India, holding a Post Graduate degree in Business Administration and Human Resource Management from Andhra University and a Degree in Law from Andhra University, Visakhapatnam.</p> <p>Balarama Krishna Desina has a corporate experience of more than a period of 15 years as a Company Secretary in various diversified organizations with specific hands-on experience in Company Law, Secretarial & NBFC Compliances. Presently Balarama Krishna Desina is a Secretarial Auditor for various listed, unlisted public Companies.</p>
4.	Disclosure of Relationships between directors (in case of appointment of a director)	Not applicable.



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited
CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India
Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2025

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended		Year ended	
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	17,484.50	15,985.24	14,242.32	62,713.75
	(b) Other income	742.30	568.09	382.53	1,930.03
	Total income	18,226.80	16,553.33	14,624.85	64,643.78
2	Expenses				
	(a) Cost of materials consumed	2,004.34	2,056.22	1,715.22	7,873.17
	(b) Employee benefits expense	2,904.42	2,586.58	2,479.29	10,219.64
	(c) Finance costs	690.18	657.87	604.77	2,495.90
	(d) Depreciation and amortisation expense	1,832.69	1,710.69	1,518.87	6,451.91
	(e) Other expenses	5,638.34	4,927.49	4,475.61	19,370.02
	Total expenses	13,069.97	11,938.85	10,793.76	46,410.64
3	Profit before tax and exceptional items [1-2]	5,156.83	4,614.48	3,831.09	18,233.14
4	Exceptional items (Refer Note 5)	-	102.96	-	102.96
5	Profit before tax [3-4]	5,156.83	4,511.52	3,831.09	18,130.18
6	Tax expense				
	(a) Current tax	1,132.00	934.48	869.00	3,872.48
	(b) Deferred tax	185.89	265.18	75.78	756.48
	Total tax expense	1,317.89	1,199.66	944.78	4,628.96
7	Profit for the period/year [5 - 6]	3,838.94	3,311.86	2,886.31	13,501.22
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of defined benefit liability / (asset)	(8.85)	(19.34)	(4.57)	(32.20)
	(b) Income-tax relating to above item	2.23	4.86	1.15	8.10
	Other comprehensive income for the period/year (net of tax)	(6.62)	(14.48)	(3.42)	(24.10)
9	Total comprehensive income for the period/year [7 + 8]	3,832.32	3,297.38	2,882.89	13,477.12
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6&7)	1,026.88	1,026.37	1,025.97	1,026.37
11	Other equity				78,352.62
12	Earnings per equity share (face value of Re. 1 each fully paid up) (Refer Note 6&7)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Basic (in Rs.)	3.74	3.23	2.82	13.16
	- Diluted (in Rs.)	3.73	3.22	2.81	13.14

Notes:

- The above standalone financial results of Vijaya Diagnostic Centre Limited ("the Company") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on July 28, 2025. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2025. An unmodified report has been issued by them thereon.
- The standalone figures for the quarter ended 31 March 2025 are the balancing figures between the audited standalone figures in respect of the full financial year and the published unaudited year to date standalone figures up to the third quarter ended 31 December 2024, which were subject to limited review.
- The Company has one reportable segment (viz. Diagnostic services) as per the requirements of Ind AS 108 "Operating Segments".
- During the previous year, the Company has incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
- During the quarter ended 30 June 2025, the Company has issued 50,833 equity shares of face value of Re. 1/- each on exercise of employee stock options.
- During the quarter ended 30 June 2025, the Company has granted 1,91,950 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 12 May 2025.
- The Board of Directors of the Company at their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ("the Appointed Date") under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company received letter with "no adverse observations" from the BSE Limited, National Stock Exchange of India Limited and SEBI on 05 December 2024, and further vide National Company Law Tribunal ("NCLT"), Hyderabad, order dated March 5, 2025 ("Order"), the Company has obtained the approval of the shareholders and the unsecured creditors vide resolutions passed at their meetings held on 25 April 2025, respectively. The Scheme is subject to the approval of the NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
- The Board of Directors at its meeting held on May 12, 2025, has proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2024-25, subject to the approval of the members at the ensuing annual general meeting.
- The results of the Company are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUNIL
CHANDRA
KONDAPALLY

Digitally signed by SUNIL
CHANDRA KONDAPALLY
Date: 2025.07.28
12:28:42 +05'30'

Sunil Chandra Kondapally
Whole-time Director
DIN Number: 01409332

Place: Hyderabad
Date: 28 July 2025

Limited Review Report on unaudited standalone financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Company”) for the quarter ended 30 June 2025 (“the Statement”).
2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

B S R and Co

Limited Review Report (Continued)
Vijaya Diagnostic Centre Limited

contains any material misstatement.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHA Digitally signed by
N KABRA BALKISHAN KABRA
Date: 2025.07.28
13:09:38 +05'30'

Balkishan Kabra

Partner

Hyderabad
28 July 2025

Membership No.: 221202
UDIN:25221202BMOCGQ8149



**VIJAYA
DIAGNOSTIC
CENTRE**

Vijaya Diagnostic Centre Limited

CIN: L85195TG2002PLC039075

Regd. Office: No. 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India

Phone: 040-23420422, Website: www.vijayadiagnostic.com, Email: ir@vijayadiagnostic.in

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2025

(Rs. in Lakhs except as stated)

Sl. No.	Particulars	Quarter ended			Year ended
		30 June 2025	31 March 2025	30 June 2024	31 March 2025
		Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1	Income				
	(a) Revenue from operations	18,805.31	17,324.25	15,621.68	68,139.01
	(b) Other income	704.84	554.86	356.40	1,831.95
	Total income	19,510.15	17,879.11	15,978.08	69,970.96
2	Expenses				
	(a) Cost of materials consumed	2,141.27	2,216.52	1,875.77	8,476.35
	(b) Employee benefits expense	3,160.71	2,840.28	2,735.50	11,215.28
	(c) Finance costs	748.54	719.11	626.51	2,674.43
	(d) Depreciation and amortisation expense	2,089.01	1,882.14	1,663.40	7,059.74
	(e) Other expenses	6,149.96	5,381.04	4,886.41	21,125.79
	Total expenses	14,289.49	13,039.09	11,787.89	50,551.59
3	Profit before tax and exceptional items [1 - 2]	5,220.66	4,840.02	4,190.19	19,419.37
4	Exceptional items (Refer Note 5)	-	102.96	-	102.96
5	Profit before tax [3 - 4]	5,220.66	4,737.06	4,190.19	19,316.41
6	Tax expense				
	(a) Current tax	1,159.63	939.87	960.87	4,117.77
	(b) Deferred tax, net	202.13	310.72	78.80	819.29
	Total tax expense	1,361.76	1,250.59	1,039.67	4,937.06
7	Profit for the period/year [5-6]	3,858.90	3,486.47	3,150.52	14,379.35
8	Other comprehensive income				
	Items that will not be reclassified to profit or loss				
	(a) Remeasurement of the defined benefit obligations	(9.58)	13.39	(4.57)	0.53
	(b) Income-tax relating to above item	2.41	(3.38)	1.15	(0.14)
	Other comprehensive income for the period/year (net of tax)	(7.17)	10.01	(3.42)	0.39
9	Total comprehensive income for the period/year [7+8]	3,851.73	3,496.48	3,147.10	14,379.74
	Profit for the period attributable to:				
	Owners of the Company	3,833.87	3,463.74	3,134.52	14,307.53
	Non controlling interests	25.03	22.73	16.00	71.82
	Other comprehensive income attributable to:				
	Owners of the Company	(6.96)	10.76	(3.42)	1.14
	Non controlling interests	(0.21)	(0.75)	-	(0.75)
	Total comprehensive income attributable to:				
	Owners of the Company	3,826.91	3,474.50	3,131.10	14,308.67
	Non controlling interests	24.82	21.98	16.00	71.07
10	Paid-up equity share capital (Face value of Re. 1 each) (Refer Note 6&7)	1,026.88	1,026.37	1,025.97	1,026.37
11	Other equity				78,545.03
12	Earnings per equity share (Face value of Re. 1 each fully paid up) (Refer Note 6&7)				
	- Basic (in Rs.)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	- Diluted (in Rs.)	3.76	3.38	3.06	13.95
		3.75	3.37	3.05	13.92

Notes:

1. The above consolidated financial results of Vijaya Diagnostic Centre Limited ("the Company") and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder, other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended).
2. The above consolidated financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on July 28, 2025. The statutory auditors have carried out limited review of the above results for the quarter ended 30 June 2025. An unmodified report has been issued by them thereon.
3. The consolidated figures for the quarter ended 31 March 2025 are the balancing figures between the audited consolidated figures in respect of the full financial year and the published unaudited year to date consolidated figures up to the third quarter ended 31 December 2024, which were subject to limited review.
4. The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
5. During the previous year, the Company has incurred an amount of Rs. 102.96 towards acquisition/restructuring related costs. These expenses had been categorised as exceptional items as these are not incurred in the ordinary course of business of operations of the Company.
6. During the quarter ended 30 June 2025, the Company has issued 50,833 equity shares of face value of Re. 1/- respectively on exercise of employee stock options.
7. During the quarter ended 30 June 2025, the Company has granted 1,91,150 employee stock options to eligible employees pursuant to the 'Employee Stock Option Plan 2018' as approved by the Nomination and Remuneration Committee of the Board of Directors at their meeting held on 12 May 2025.
8. The Board of Directors of the Company at their meeting held on 26 June 2024, have considered and approved the proposed Scheme of Amalgamation ("Scheme") wherein Medinova Diagnostic Services Limited (Subsidiary Company) would merge into the Company with effect from 01 April 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company received letter with "no adverse observations" from the BSE Limited, National Stock Exchange of India Limited and SEBI on 05 December 2024, and further vide National Company Law Tribunal ("NCLT"), Hyderabad, order dated March 5, 2025 ("Order"), the Company has obtained the approval of the shareholders and the unsecured creditors vide resolutions passed at the their meetings held on 25 April 2025, respectively. The Scheme is subject to the approval of the NCLT, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.
9. The Board of Directors at its meeting held on May 12, 2025, has proposed and recommended dividend of Re. 2/- per equity share of Re. 1 each i.e., 200% for the financial year 2024-25, subject to the approval of the members at the ensuing annual general meeting.
10. The results of the Group are available for investors at www.vijayadiagnostic.com, www.nseindia.com and www.bseindia.com.

for and on behalf of the Board of Directors of
Vijaya Diagnostic Centre Limited

SUNIL
CHANDRA
KONDAPALLY

Digitally signed by
SUNIL CHANDRA
KONDAPALLY
Date: 2025.07.28
12:27:49 +05'30'

Sunil Chandra Kondapally
Whole-time Director
DIN Number: 01409332

Place: Hyderabad
Date: 28 July 2025

Limited Review Report on unaudited consolidated financial results of Vijaya Diagnostic Centre Limited for the quarter ended 30 June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Vijaya Diagnostic Centre Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Vijaya Diagnostic Centre Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 June 2025 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “*Interim Financial Reporting*” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent

- a. Vijaya Diagnostic Centre Limited

Subsidiaries

- b. Medinova Diagnostic Services Limited
- c. VDC Diagnostic (Karnataka) LLP
- d. Medinova Millenium MRI Services LLP
- e. P H Diagnostic Centre Private Limited
- f. Namrata Diagnostic Centre Private Limited (Struck off on 06 April 2024)
- g. Doctorslab Medical Services Private Limited (Struck off on 06 April 2024)

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2025 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

Principal Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center,
Western Express Highway, Goregaon (East), Mumbai - 400063

Limited Review Report (Continued)

Vijaya Diagnostic Centre Limited

6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial results of four subsidiaries (including one step down subsidiary) included in the Statement, whose interim financial results reflect total revenues (before consolidation adjustments) of Rs. 1,360.00 lakhs, total net profit after tax (before consolidation adjustments) of Rs. 52.61 lakhs, total comprehensive income (before consolidation adjustments) of Rs. 52.06 lakhs for the quarter ended 30 June 2025, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

For **B S R and Co**

Chartered Accountants

Firm's Registration No.:128510W

BALKISHA Digitally signed by
BALKISHAN KABRA
N KABRA Date: 2025.07.28
13:08:52 +05'30'

Balkishan Kabra

Partner

Hyderabad

28 July 2025

Membership No.: 221202

UDIN:25221202BMOCGP8622